NCT06059274

Brief Summary

The study aimed to evaluate the effectiveness and tolerability of a dermocosmetic serum containing hyaluronic acid, vitamin B5, madecassoside and La Roche-Posay Thermal Spring Water in reducing skin aging signs. The experimental clinical trial involved 34 participants aged 45 to 65 years who applied the serum twice a day for 84 days.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
34

participants targeted

Target at P25-P50 for not_applicable

Timeline
Completed

Started Mar 2018

Shorter than P25 for not_applicable

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

March 14, 2018

Completed
Same day until next milestone

Primary Completion

Last participant's last visit for primary outcome

March 14, 2018

Completed
3 months until next milestone

Study Completion

Last participant's last visit for all outcomes

June 7, 2018

Completed
5.3 years until next milestone

First Submitted

Initial submission to the registry

September 23, 2023

Completed
5 days until next milestone

First Posted

Study publicly available on registry

September 28, 2023

Completed
Last Updated

October 2, 2023

Status Verified

September 1, 2023

Enrollment Period

Same day

First QC Date

September 23, 2023

Last Update Submit

September 28, 2023

Conditions

Keywords

anti-agingskin barrierdermocosmeticwrinkles

Outcome Measures

Primary Outcomes (3)

  • Instrumental Assessment - Primos® Optical 3D

    The Primos® Optical 3D (Canfield) device in vivo allows the measurement and evaluation of wrinkles through the technique of fringed projection, based on digital mirrors (DMDTM: Digital Mirco mirror Devices) directly on the skin surface of the participants.

    from baseline to Day 84

  • Clinical assessment through Visual Analog Scale (VAS)

    The dermatologist investigates the degree of roughness of the frontal, peri-orbital, peri-oral, neck and overall aspect according to the following parameters: number of wrinkles (no wrinkles / several wrinkles), wrinkles thickness (very thin wrinkle / very thick wrinkle), length of the wrinkle (very short wrinkle / very long wrinkle), depth of wrinkle (very superficial wrinkle / very deep wrinkle) on a line from 0 to 10.

    from baseline to Day 84

  • Clinical assessment using the standard scale "Skin Aging Atlas"

    The dermatologist investigates the frontal, peri-orbital, peri-oral and neck regions, comparing the roughness observed in the research regions with the images presented in the Skin Aging Atlas, establishing, for each area, a degree of roughness, that made possible the evaluation in the different experimental times.

    from baseline to Day 84

Secondary Outcomes (1)

  • Instrumental Assessment - VISIA-6®

    from baseline to Day 84

Study Arms (1)

Topical serum

EXPERIMENTAL

An investigational topical serum containing hyaluronic acid, vitamin B5, madecassoside and La Roche-Posay Thermal Spring Water

Other: Topical serum

Interventions

Participants are asked to apply the topical serum twice daily for 84 days.

Topical serum

Eligibility Criteria

Age45 Years - 65 Years
Sexfemale
Healthy VolunteersYes
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • phototype I to IV
  • presenting wrinkles on the forehead and/or peri-orbital area with grade ≥ 2 and ≤4 according to "Skin Aging Atlas"
  • participant has not used any anti-aging products or performed aesthetic procedures over the last three months

You may not qualify if:

  • pregnant, breastfeeding or immune compromised woman
  • participant with cutaneous marks or active dermatoses on the tested area that could interfere with the evaluation

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

CIDP Brasil

Rio de Janeiro, Brazil

Location

Study Officials

  • Joana Carvalho

    Centre International de Développement Pharmaceutique (CIDP)

    PRINCIPAL INVESTIGATOR

Study Design

Study Type
interventional
Phase
not applicable
Allocation
NA
Masking
NONE
Purpose
TREATMENT
Intervention Model
SINGLE GROUP
Sponsor Type
INDUSTRY
Responsible Party
SPONSOR

Study Record Dates

First Submitted

September 23, 2023

First Posted

September 28, 2023

Study Start

March 14, 2018

Primary Completion

March 14, 2018

Study Completion

June 7, 2018

Last Updated

October 2, 2023

Record last verified: 2023-09

Locations